Sprint Bioscience AB Cash Flow Conversion Efficiency

Latest as of March 2026: -0.182x

Sprint Bioscience AB cash flow conversion efficiency. Based on the latest financial reports, Sprint Bioscience AB (SPRINT) has a cash flow conversion efficiency ratio of -0.182x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-19.29 Million ≈ $-2.08 Million USD) by net assets (Skr106.29 Million ≈ $11.44 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Cash Flow Conversion Efficiency of Sprint Bioscience AB (2012–2025)

Cash flow conversion efficiency of Sprint Bioscience AB from 2012 to 2025. This chart illustrates how Sprint Bioscience AB's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Sprint Bioscience AB (SPRINT) stock price for real-time trading data and today's change.

Sprint Bioscience AB Cash Flow Conversion Ratio Explained

Sprint Bioscience AB cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.

Sprint Bioscience AB Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Sprint Bioscience AB ranked by their cash flow conversion efficiency. Also see market cap of Sprint Bioscience AB for the company's overall valuation and market capitalisation.

Company	Cash Flow Conversion Efficiency
Taiwan Benefit Co TWO:3379	-0.100x
Dividend Select 15 Corp TO:DS	0.006x
Hyundai HT CoLtd KQ:039010	0.046x
Anson Resources Ltd AU:ASN	-0.058x
MClean Technologies Bhd KLSE:0167	0.040x
Eightco Holdings Inc. NASDAQ:OCTO	-0.078x
H2APEX Group SCA XETRA:H2A	-0.376x
ACELRX PHARMACEUT. DL-01 F:R5XA	-0.143x

Annual Cash Flow Conversion Efficiency for Sprint Bioscience AB (2012–2025)

The table below shows the annual cash flow conversion efficiency of Sprint Bioscience AB from 2012 to 2025. Review how much free cash does Sprint Bioscience AB generate to assess how much free cash flow the company generates relative to operating cash flow.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	Skr119.18 Million ≈ $12.83 Million	Skr83.53 Million ≈ $8.99 Million	0.701x	+127.83%
2024-12-31	Skr9.27 Million ≈ $997.82K	Skr-23.36 Million ≈ $-2.51 Million	-2.519x	-405.90%
2023-12-31	Skr27.77 Million ≈ $2.99 Million	Skr22.87 Million ≈ $2.46 Million	0.823x	+139.31%
2022-12-31	Skr28.19 Million ≈ $3.03 Million	Skr-59.05 Million ≈ $-6.36 Million	-2.095x	-267.93%
2021-12-31	Skr70.45 Million ≈ $7.58 Million	Skr-40.12 Million ≈ $-4.32 Million	-0.569x	+83.84%
2020-12-31	Skr9.14 Million ≈ $984.04K	Skr-32.22 Million ≈ $-3.47 Million	-3.524x	-38.64%
2019-12-31	Skr11.02 Million ≈ $1.19 Million	Skr-28.00 Million ≈ $-3.01 Million	-2.542x	-396.07%
2018-12-31	Skr37.24 Million ≈ $4.01 Million	Skr-19.08 Million ≈ $-2.05 Million	-0.512x	+37.56%
2017-12-31	Skr28.09 Million ≈ $3.02 Million	Skr-23.05 Million ≈ $-2.48 Million	-0.821x	-394.71%
2016-12-31	Skr28.49 Million ≈ $3.07 Million	Skr7.93 Million ≈ $853.92K	0.278x	+61.03%
2015-12-31	Skr4.82 Million ≈ $518.74K	Skr833.54K ≈ $89.70K	0.173x	+132.66%
2014-12-31	Skr20.32 Million ≈ $2.19 Million	Skr-10.76 Million ≈ $-1.16 Million	-0.529x	+50.07%
2013-12-31	Skr3.36 Million ≈ $361.91K	Skr-3.57 Million ≈ $-383.76K	-1.060x	+49.25%
2012-12-31	Skr1.10 Million ≈ $118.06K	Skr-2.29 Million ≈ $-246.66K	-2.089x	--

About Sprint Bioscience AB

ST:SPRINT Sweden Biotechnology

Market Cap

$38.95 Million

Skr361.92 Million SEK

Market Cap Rank

#22613 Global

#426 in Sweden

Share Price

Skr3.43

Change (1 day)

+2.08%

52-Week Range

Skr0.64 - Skr4.49

All Time High

Skr47.75